Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest

Journal of the American College of Cardiology

Volumn 30, Issue 2, 1997, Pages 487-495

  Haverkamp, Wilhelm ^a   Martinez Rubio, Antonio ^a   Hief, Christiene ^a   Lammers, Andreas ^a   Mühlenkamp, Stefan ^a   Wichter, Thomas ^a   Breithardt, Günter ^a   Borggrefe, Martin ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; SOTALOL;

ADULT; AGED; ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROPHYSIOLOGY; ELECTROSTIMULATION; FEMALE; HEART ARREST; HEART DEATH; HEART VENTRICLE TACHYCARDIA; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL RATE; TORSADE DES POINTES;

ADMINISTRATION, ORAL; ANTI-ARRHYTHMIA AGENTS; ELECTRIC STIMULATION; FEMALE; FOLLOW-UP STUDIES; HEART ARREST; HUMANS; MALE; MIDDLE AGED; SOTALOL; TACHYCARDIA, VENTRICULAR; TORSADES DE POINTES; VENTRICULAR FIBRILLATION;

EID: 0030818655     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(97)00190-3     Document Type: Article

References (28)

1. Singh BN, Nademanee K. Sotalol a beta-blocker with unique antiarrhythmic properties . Am Heart J. 114:1987;121-139.
2. Hohnloser SH, Woosley RL. D,l-sotalol. N Engl J Med. 331:1994;31-38.
3. Borggrefe M, Trampisch HJ, Breithardt G. Reappraisal of criteria assessing drug efficacy in patients with ventricular tachyarrhythmias complete versus partial suppression of inducible arrhythmias . J Am Coll Cardiol. 12:1988;140-149.
4. SPSS for Windows Release 5 . 1992;SPSS Inc, Chicago.
5. Lish PM, Weikel JH, Dungan KW. Pharmacological and toxicological properties of two new beta-adrenergic receptor antagonists. J Pharmacol Exp Ther. 149:1965;161-173.
6. Kaumann AJ, Olson CB. Temporal relation between long-lasting aftercontractions and action potentials in cat papillary muscles. Science. 161:1968;293-295.
7. Senges J, Lengfelder W, Jauering R, et al. Electrophysiologic testing in assessment of therapy with d,l-sotalol for sustained ventricular tachycardia. Circulation. 69:1984;577-584.
8. Steinbeck G, Bach P, Haberl R. Electrophysiologic and antiarrhythmic efficacy of oral d,l-sotalol for sustained ventricular tachyarrhythmias evaluation by programmed stimulation and ambulatory electrocardiogram . J Am Coll Cardiol. 8:1986;949-958.
9. Singh SN, Cohen A, Chen Y, et al. Sotalol for refractory sustained ventricular tachycardia and nonfatal cardiac arrest. Am J Cardiol. 62:1988;399-402.
10. Kienzle MG, Martins JB, Wendt DJ, Constantin L, Hopson R. Enhanced efficacy of oral sotalol for sustained ventricular tachycardia refractory to type I antiarrhythmic drugs. Am J Cardiol. 61:1988;1012-1017.
11. Jordaens LJ, Palmer A, Clement DL. Low-dose oral sotalol for monomorphic ventricular tachycardia effects during programmed electrical stimulation and follow-up . Eur Heart J. 10:1989;218-226.
12. Nademanee K, Singh BN. Effects of d,l-sotalol on ventricular tachycardia and fibrillation produced by programmed electrical stimulation comparison with other antiarrhythmic agents . Am J Cardiol. 65:1990;53A-57A.
13. Obel IWP, Jardine R, Haitus B, Scott Millar RN. Efficacy of oral sotalol in reentrant ventricular tachycardia. Cardiovasc Drugs Ther. 4:(Suppl 3):1990;613-618.
14. Trappe HJ, Klein H, Lichtlen P. Sotalol in patients with life-threatening ventricular tachyarrhythmias. Cardiovasc Drugs Ther. 4:1990;1425-1432.
15. Kus T, Campa MA, Nadeau R, et al. Efficacy and electrophysiologic effects of oral d,l-sotalol in patients with sustained ventricular tachycardia due to coronary artery disease. Am Heart J. 123:1992;82-90.
16. Young GD, Kerr CR, Mohama R, Boone J, Yeung-Lai-Wah JA. Efficacy of sotalol guided by programmed electrical stimulation for sustained ventricular arrhythmias secondary to coronary artery disease. Am J Cardiol. 73:1994;677-682.
17. Kehoe RF, MacNeil DJ, Zheutlin TA, et al. Safety and efficacy of oral d,l-sotalol for sustained ventricular tachyarrhythmias refractory to other antiarrhythmic agents. Am J Cardiol. 72:1993;56A-60A.
18. Gonzales R, Scheinmann MM, Herre JM, Griffin JC, Sauve MJ, Sharkey H. Usefulness of sotalol for drug-refractory malignant ventricular arrhythmias. J Am Coll Cardiol. 12:1988;1568-1572.
19. Ruder MA, Ellis T, Lebsack C, Mead RH, Smith NA, Winkle RA. Clinical experience with d,l-sotalol in patients with drug-refractory ventricular arrhythmias. J Am Coll Cardiol. 13:1989;145-152.
20. Kuchar DL, Garan H, Venditti FJ, et al. Usefulness of d,l-sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts. Am J Cardiol. 64:1989;33-36.
21. Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med. 329:1993;452-458.
22. Meissner MD, Kay HR, Horowitz LN, Spielman SR, Greenspan AM, Kutalek SP. Relation of acute antiarrhythmic drug efficacy to left ventricular function in coronary artery disease. Am J Cardiol. 61:1988;1050-1055.
23. Budde T, Borggrefe M, Podczeck A, Martinez-Rubio A, Breithardt G. Acute and long-term efficacy of oral propafenone in patients with ventricular tachyarrhythmias. J Cardiovasc Pharmacol. 18:1991;254-260.
24. Boersma L, Brugada J, Abdollah H, Kirchhof C, Allessie M. Effects of heptanol, class Ic, and class III drugs on reentrant ventricular tachycardia importance of the excitable gap for the inducibility of double-wave reentry . Circulation. 90:1994;1012-1022.
25. Brugada J, Boersma L, Kirchhof C, et al. Double-wave reentry as a mechanism of ventricular tachycardia acceleration. Circulation. 81:1990;1633-1643.
26. Leclercq JF, Coumel P. Characteristics, prognosis and treatment of the ventricular arrhythmias of right ventricular dysplasia. Eur Heart J. 10:(Suppl D):1989;61-65.
27. Soyka LF, Wirtz C, Spangenberg RB. Clinical safety profile of d,l-sotalol in patients with arrhythmias. Am J Cardiol. 65:1990;74A-81A.
28. Böcker D, Haverkamp W, Block M, Borggrefe M, Hammel D, Breithardt G. Comparison of d,l-sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease. Circulation. 94:1996;151-157.